The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
Open accessAbstract
BACKGROUND & AIMS: Categorization of colon cancers into distinct subtypes using a combination of pathway-based biomarkers could provide insight into stage-independent variability in outcomes. METHODS: We used a polymerase chain reaction-based assay to detect mutations in BRAF (V600E) and in KRAS in 2720 stage III cancer samples, collected prospectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147). Tumors deficient or proficient in DNA mismatch repair (MMR) were identified based on detection of MLH1, MSH2, and MSH6 proteins and methylation of the MLH1 promoter. Findings were validated using tumor samples from a separate set of patients with stage III cancer (n = 783). Association with 5-year disease-free survival was evaluated using Cox proportional hazards models. RESULTS: Tumors were categorized into 5 subtypes based on MMR status and detection of BRAF or KRAS mutations which were mutually exclusive. Three subtypes were MMR proficient: those with mutations in BRAF (6.9% of samples), mutations in KRAS (35%), or tumors lacking either BRAF or KRAS mutations (49%). Two subtypes were MMR deficient: the sporadic type (6.8%) with BRAF mutation and/or or hypermethylation of MLH1 and the familial type (2.6%), which lacked BRAF(V600E) or hypermethylation of MLH1. A higher percentage of MMR-proficient tumors with BRAF(V600E) were proximal (76%), high-grade (44%), N2 stage (59%), and detected in women (59%), compared with MMR-proficient tumors without BRAF(V600E) or KRAS mutations (33%, 19%, 41%, and 42%, respectively; all P < .0001). A significantly lower proportion of patients with MMR-proficient tumors with mutant BRAF (hazard ratio = 1.43; 95% confidence interval: 1.11-1.85; Padjusted = .0065) or mutant KRAS (hazard ratio = 1.48; 95% confidence interval: 1.27-1.74; Padjusted < .0001) survived disease-free for 5 years compared with patients whose MMR-proficient tumors lacked mutations in either gene. Disease-free survival rates of patients with MMR-deficient sporadic or familial subtypes was similar to those of patients with MMR-proficient tumors without BRAF or KRAS mutations. The observed differences in survival rates of patients with different tumor subtypes were validated in an independent cohort. CONCLUSIONS: We identified subtypes of stage III colon cancer, based on detection of mutations in BRAF (V600E) or KRAS, and MMR status that show differences in clinical and pathologic features and disease-free survival. Patients with MMR-proficient tumors and BRAF or KRAS mutations had statistically shorter survival times than patients whose tumors lacked these mutations. The tumor subtype found in nearly half of the study cohort (MMR-proficient without BRAF(V600E) or KRAS mutations) had similar outcomes to those of patients with MMR-deficient cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“BRAF is a member of the Raf kinase family that is a regulator of the MAP kinase/ERK signaling pathway.(7,8) BRAF mutations occur downstream from and are mutually exclusive of KRAS codon 12 and 13 mutations(8) that are detected in 30%–40% of CRCs.”
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
AJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623
Self-citationJass, J. R. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02549.x · Cited by 1,384
RAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 2×
“BRAF is a member of the Raf kinase family that is a regulator of the MAP kinase/ERK signaling pathway.(7,8) BRAF mutations occur downstream from and are mutually exclusive of KRAS codon 12 and 13 mutations(8) that are detected in 30%–40% of CRCs.”
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Self-citationKuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Role of the Serrated Pathway in Colorectal Cancer Pathogenesis
Leggett, B., & Whitehall, V. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.066 · Cited by 977
Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
Grady, W. M., & Carethers, J. M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.076 · Cited by 960
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., Giovannucci, E. L., & Fuchs, C. S. (2009) · Gut · doi:10.1136/gut.2008.155473 · Cited by 777
De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771 · cited 2×
“Gene expression profiling of mutant BRAF pMMR cancers reveals up-regulation of genes regulating epithelial mesenchymal transition and matrix remodeling that can facilitate tumor invasion and metastasis and, thereby, contribute to their poor outcome.(37) Results in the overall cohort were maintained in proximal cancers…”
Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers
Samowitz, W. S., Sweeney, C., Herrick, J., Albertsen, H., Levin, T. R., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0404 · Cited by 737
Yothers, G., O'Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4539 · Cited by 656
Sinicrope, F. A., Foster, N. R., Thibodeau, S. N., Marsoni, S., Monges, G., Labianca, R., Yothers, G., Allegra, C., Moore, M. J., Gallinger, S., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr153 · Cited by 543
Self-citationSargent, D. J. (2012) · JAMA · doi:10.1001/jama.2012.385 · Cited by 501
Self-citationMorphology of sporadic colorectal cancer with DNA replication errors
Jass, J. R., Do, K.-A., Simms, L. A., Iino, H., Wynter, C., Pillay, S. P., Searle, J., Radford-Smith, G., Young, J., & Leggett, B. (1998) · Gut · doi:10.1136/gut.42.5.673 · Cited by 466
Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival
Phipps, A. I., Limburg, P. J., Baron, J. A., Burnett-Hartman, A. N., Weisenberger, D. J., Laird, P. W., Sinicrope, F. A., Rosty, C., Buchanan, D. D., Potter, J. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.038 · Cited by 401
Self-citationSamowitz, W. S., Curtin, K., Schaffer, D., Robertson, M. A., Leppert, M., & Slattery, M. L. (2000) · PubMed · Cited by 351
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing
Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., Westra, J., Frebourg, T., Espín, E., Armengol, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020651 · Cited by 339
Self-citationGavin, P. G., Colangelo, L. H., Fumagalli, D., Tanaka, N., Remillard, M. Y., Yothers, G., Kim, C., Taniyama, Y., Kim, S. I., Choi, H. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0605 · Cited by 320
Sinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
Self-citationSinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 279
Self-citationOgino, S., Shima, K., Meyerhardt, J. A., McCleary, N. J., Ng, K., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2246 · Cited by 267
Self-citationFariña-Sarasqueta, A., van Lijnschoten, G., Moerland, E., Creemers, G.-J., Lemmens, V. E. P. P., Rutten, H. J. T., & van den Brule, A. J. C. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq258 · Cited by 263
Imamura, Y., Morikawa, T., Liao, X., Lochhead, P., Kuchiba, A., Yamauchi, M., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., Haigis, K. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3210 · Cited by 249
Phipps, A. I., Buchanan, D. D., Makar, K. W., Win, A. K., Baron, J. A., Lindor, N. M., Potter, J. D., & Newcomb, P. A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.118 · Cited by 238
GRADY, W., RAIPUT, A., LUTTERBAUGH, J., & MARKOWITZ, S. (2001) · Gastroenterology · doi:10.1016/s0016-5085(01)81443-8 · Cited by 224
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.014 · Cited by 216
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
Ogino, S., Meyerhardt, J. A., Irahara, N., Niedzwiecki, D., Hollis, D., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., Hantel, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1570 · Cited by 194
Self-citationDomingo, E., Niessen, R. C., Oliveira, C., Alhopuro, P., Moutinho, C., Espín, E., Armengol, M., Sijmons, R. H., Kleibeuker, J. H., Seruca, R., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208569 · Cited by 177
Hinoue, T., Weisenberger, D. J., Pan, F., Campan, M., Kim, M.-J., Young, J. P., Whitehall, V., Leggett, B., & Laird, P. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008357 · Cited by 159
Carragher, L. A. S., Snell, K. R., Giblett, S. M., Aldridge, V. S. S., Patel, B., Cook, S. J., Winton, D. J., Marais, R., & Pritchard, C. A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000099 · Cited by 144
Phipps, A. I., Buchanan, D. D., Makar, K. W., Burnett‐Hartman, A. N., Coghill, A. E., Passarelli, M. N., Baron, J. A., Ahnen, D. J., Win, A. K., Potter, J. D., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0674 · Cited by 144
Kim, Y. H., Kakar, S., Cun, L., Deng, G., & Kim, Y. S. (2008) · International Journal of Cancer · doi:10.1002/ijc.23840 · Cited by 130
Fraser, D. A. S., & Wormleighton, R. (1951) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177729650 · Cited by 112
Angulo, B., García-García, E., Martínez, R., Suárez‐Gauthier, A., Conde, E., Hidalgo, M. M., & López‐Ríos, F. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090139 · Cited by 110
Burnett‐Hartman, A. N., Newcomb, P. A., Potter, J. D., Passarelli, M. N., Phipps, A. I., Wurscher, M. A., Grady, W. M., Zhu, L., Upton, M. P., & Makar, K. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3462 · Cited by 84
Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution
Sylvester, B. E., Huo, D., Khramtsov, A., Zhang, J., Smalling, R. V., Olugbile, S. O., Polite, B. N., & Olopade, O. I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1397 · Cited by 69
Samadder, N. J., Vierkant, R. A., Tillmans, L. S., Wang, A. H., Weisenberger, D. J., Laird, P. W., Lynch, C. F., Anderson, K. E., French, A. J., Haile, R. W., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.001 · Cited by 55
Self-citationSomatic gene mutations in African Americans may predict worse outcomes in colorectal cancer
Kang, M. S., Shen, X., Kim, S., Araújo-Pérez, F., Galanko, J. A., Martin, C. F., Sandler, R. S., & Keku, T. O. (2013) · Cancer Biomarkers · doi:10.3233/cbm-130366 · Cited by 44
Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
Bond, C., Umapathy, A., Buttenshaw, R. L., Wockner, L. F., Leggett, B., & Whitehall, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047483 · Cited by 25
Cited by
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
“It will also accelerate the application of gene classifications to cell lines, organoids and patient-derived xenograft models with drug sensitivity data.”
Self-citationGlobal colorectal cancer burden in 2020 and projections to 2040
Xi, Y., & Xu, P. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101174 · Cited by 2,434
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
“BRAF mutations frequently coexist with high microsatellite instability and provide modest prognostic information for recurrence.(4,5) Patients with metastatic BRAF-mutated CRC have a poor prognosis, with a median survival of approximately 12 months despite the utilization of combination chemotherapy.”
BackgroundAndré, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683
Deep learning based tissue analysis predicts outcome in colorectal cancer
Bychkov, D., Linder, N., Turkki, R., Nordling, S., Kovanen, P. E., Verrill, C., Walliander, M., Lundin, M., Haglund, C., & Lundin, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-21758-3 · Cited by 644
Metadata
- Authors
- Sinicrope, F. A., Shi, Q., Smyrk, T. C., Thibodeau, S. N., Dienstmann, R., Guinney, J., Bot, B. M., Tejpar, S., Delorenzi, M., Goldberg, R. M., Mahoney, M., Sargent, D. J., & Alberts, S. R.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 148
- Issue
- 1
- Pages
- 88-99
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2136532871
- Cited by
- 330
- References
- 56
- FWCI
- 25.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.